OREANDA-NEWS. On 04 August 2008 was announced, that in concordance with the signed agreement, as of July 2008, the Russian JSC FarmFirma Soteks has begun to manufacture the injection form of Grindeks original product Mildronate®.

JSC Grindeks Board Member, Director of the Final Dosage Forms Manufacturing Lipmans Zeligmans emphasizes the importance of the agreement: „As a result of the active, two year long cooperation, the manufacturing of injection form of the leading original product Mildronate® from Grindeks will be launched also in Russia, and this will make Mildronate® even more accessible to Russian customers. We chose the manufacturing partner in Russia carefully and selected a JSC FarmFirma Soteks. In comparison with other Russian enterprises, its manufacturing infrastructure complies with the standards and technological requirements of Good manufacturing practice, which is necessary for the manufacturing of the Mildroate® injections. Our specialists have performed the audit of the FarmFirma Soteks production unit, and, together with the specialists from Farmfirma Soteks, have secured the introduction of manufacturing technology. “

In concordance with the contracts signed before, the manufacturing of the Grindeks injection forms will be continued by the pharmaceutical enterprise Sanitas in Lithuania, and by the JSC Jelfa SA in Poland.

Grindeks subsidiary Tallinn Pharmaceutical plant in Estonia specializes in ointment manufacturing. In Latvia Grindeks manufactures tablets, capsules and syrups. A considerable expansion of the infrastructure takes place now in manufacturing plant in Latvia. After the plant will be audited in the autumn of 2008, the capacity of manufacturing will increase to 1.5 billion tablets and 500 million capsules per year.

As informed before, within the framework of the agreement (from February 2008), OJSC Farmstandart performs the exclusive sales and promotion of Grindeks original product Mildronate® in the territory of Russian Federation, including manufactured by FarmFirma Soteks.

JSC Grindeks is the leading pharmaceutical company in the Baltic States. Its main fields of action are: research, development and manufacturing of brand products, generics and active pharmaceutical ingredients. Grindeks specializes in the heart and cardiovascular, CNS and anti-cancer medication therapeutic groups.

A range of Grindeks’s products covers a successful combination of original products and generics, with the original products Mildronate® and Ftorafur® and more than 100 forms of effective and safe generics included therein.

Grindeks concern consists of four subsidiary companies in Latvia, Estonia and Russia, as well representatives and representative offices in fourteen countries. Products of the company are exported to more than 40 countries and its export comprises more than 96% of the total turnover. The main markets are: the Baltic States, Russia and other CIS countries, Japan, USA. Grindeks shares are listed in the Official List of Riga Stock Exchange.